Introduction {#s1}
============

Phenotyping for drug metabolizing enzymes and transporters using simultaneous administration of selective substrates is frequently adopted in drug interaction studies. By appropriate choice of drug probes, phenotypic metrics, and sampling times, this "cocktail" approach enables concomitant assessment of the activity of drug metabolizing enzymes and transporters with economy of scale, both in terms of costs and time. Several cocktails have been developed since the pioneer work of [@B17], and comprehensively reviewed by different authors ([@B10]; [@B6]; [@B11]). A common feature of many cocktails is the use of single timed blood and/or urine sample(s) for quantification of the probe drugs and/or their metabolite(s), and inference of pharmacokinetic parameters to be used as phenotypic indices. The present article examines the impact of increasing the number of sampling time-points on the accuracy of phenotypic metrics for cytochrome P450 (CYP) enzymes and the ABCB1 transporter. We applied limited sampling strategy (LSS) modeling to plasma concentration data from a trial in which a cocktail of subtherapeutic doses of selective probes was used to investigate the effects of a Brazilian propolis extract on the metabolic activity of CYP enzymes (CYP1A2, CYP2C9, CYP2C19, and CY2D6) and the drug transporter ABCB1 ([@B4]). Propolis is a resinous balsamic material, with a complex chemical composition, that is collected by bees from sprouts, exudates of trees, and other parts of the plant sand mixed with wax and bee enzyme ([@B18]). The formulation used, which consists predominantly of green propolis from *Baccharis dracuncufolia*, was reported to have no clinically-relevant effect on the activity of the CYP enzymes examined or the ABCB1 drug transporter ([@B4]). The results of the present study show that single-point LSS models for metoprolol and omeprazole provide highly accurate estimates of the metabolic activity of CYP2C19 and CYP2D6, but 2-point LSS models are required to obtain comparable accuracy when caffeine, midazolam, or fexofenadine are used as probes for CYP1A2, CYP3A, and the drug transporter, ABCB1, respectively.

Methods {#s2}
=======

Study Protocol {#s2_1}
--------------

Details of the original trial, which was approved by the Ethics Committee of the Teaching Hospital of the Ribeirão Preto Medical School, University of São Paulo, and the effects of the propolis formulation have been published elsewhere ([@B4]). Briefly, 16 healthy adults (11 men) ingested, on two occasions separated by 15 days, a capsule containing subtherapeutic doses of the phenotypic probes caffeine (10 mg; probe for CYP1A2), losartan (2 mg; CYP2C9), metoprolol (10 mg; CYP2D6), midazolam (0.2 mg; CYP3A), omeprazole (2 mg; CYP2C19), and fexofenadine (10 mg; ABCB1). During the 15 days between the two study phases, the subjects self-administered three oral daily doses of 125 mg of a standardized propolis formulation, namely EPP-AF^®^ (Apis Flora, Ribeirão Preto, SP, Brazil). Subjects were instructed to avoid caffeine-containing beverages in the five days preceding each study phase. In the two study phases, consecutive blood samples were collected immediately before (zero time) and 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 480, 600, and 720 min after ingestion of the phenotypic probes. The plasma concentrations of each probe and of metabolites of losartan (E-3174), metoprolol (α-OH metoprolol), and omeprazole (5-OH omeprazole) were quantified by validated LC/MS/MS methods ([@B5]). The area under the plasma concentration *versus* time curve between 0 and 720 min (AUC~0--12h~) of the probes and metabolites was calculated using the trapezoidal method. The AUC~0--12h~ thus obtained is taken as the "best estimate" of the respective parameter value ([@B21]; [@B22]).

Development of LSS Models {#s2_2}
-------------------------

All-subsets linear regression analysis ([@B15]) was applied to the plasma drug concentration data sets from the first study phase ("training set") for development of LSS models to predict the AUC~0--12h~ of caffeine, fexofenadine, midazolam, and the ratio of AUC~0--12h~s of metoprolol and omeprazole to their respective metabolites. We did not attempt to develop LSS models for losartan as a CYP2C9 probe, in view of the high plasma concentrations of the metabolite E-3174 in the last sample collected in both study phases. This suggested to us that the AUC~0--12h~ of E-3174 is not a reliable biomarker of CYP2C9-mediated conversion of losartan into E-3174.

A total of 1,320 plasma concentration data points were available for LSS development. In addition to the plasma concentration data, *CYP2C19* and *CYP2D6* genotypes and inferred phenotypes were available for all subjects enrolled in the trial ([@B4]). One subject classified as CYP2D6 poor metabolizer (genotype *CYP2D6\*4/\*4)* was excluded from the LSS modeling for metoprolol:α-OH metoprolol, since the plasma concentration of the metabolite was below the limit of quantification in most samples. Two subjects identified as intermediate CYP2C19 metabolizers (genotype *CYP2C19\*1/\*2*) were included in the LSS modeling for omeprazole:5-OH omeprazole.

LSS models to predict the AUC~0--12h~ of caffeine, fexofenadine, and midazolam were derived using the respective drug plasma concentrations. In the case of metoprolol and omeprazole, the ratio of plasma concentrations of probe:metabolite at each sample time was used to develop LSS models to predict the ratio of the AUC~0--12h~ of probe:metabolite. Computations were performed using function leaps ([@B12]) in the R package software, version 3.5.0. This analysis produced linear equations of the following form: AUC~0--12h~ = *Ao* + *A*1\**C*1 + *A*2\**C*2.... + *An\* Cn*, where *Ao* is an intercept, *An* are coefficients, and *Cn* are plasma concentration data at particular sampling times. Regression equations were ranked according to the correlation coefficient (*R* ^2^) criterium in order to identify those that provided the best fit for *n* timed plasma samples. The LSS-predicted AUC~0--12h~ of caffeine, midazolam, and fexofenadine, and LSS-predicted ratio of AUC~0--12h~s of metoprolol: α-OH metoprolol and omeprazole:5-OH omeprazole were then compared with the corresponding individual best estimates of the respective metrics. The bias of the LSS-derived estimates was assessed by calculating the mean percentage of difference (MD%) from the best estimates as follows: MD% = \[(derived estimate - best estimate)/best estimate\]\*100%. Precision was assessed by calculating the mean absolute percentage of difference (MAD%) as follows: MAD% = \[(\|derived estimate - best estimate\|)/best estimate\]\*100 ([@B21]; [@B22]). Linear correlation and Bland--Altman plots ([@B1]) were used to visualize the agreement between best-estimated and LSS-predicted metrics for each probe.

Validation of the LSS Models {#s2_3}
----------------------------

The LSS models were validated using two procedures: first, the LSS equations derived from the training set (first study phase) were used to estimate the corresponding AUC~0--12h~s or ratio of probe:metabolite AUC~0--12h~s using the concentrations observed at the same respective times in the second study phase (validation set; n = 1,320 samples). The AUC~0--12h~s or ratio of probe:metabolite AUC~0--12h~s thus obtained were then compared to the best estimates of the respective metric.

As a second validation approach, we used the jack-knife prediction ([@B14]) which is made by systematically leaving out one data set and using the *n-1* remaining data sets to develop LSS models with the same sampling times as the LSS equation that is being validated. Thus, *n* slightly different regression equations are obtained, and each of them is used to predict the AUC~0--12h~ or AUC~0--12h~ ratio for the data set that was left out. By discarding one data set at a time and fitting a new model for the *n* − 1 remaining data sets, the particular data set that is omitted does not influence the estimation of the regression parameters. The jack-knife validation was applied separately to the data sets of the two study phases. Linear correlation plots were constructed to visualize the agreement between best-estimated and LSS-predicted AUC~0--12h~ metrics using the jack-knife approach.

Statistical Analysis {#s2_4}
--------------------

The specific statistical tests applied to the data are indicated in the text. Significance level was set at a *P* value \< 0.05.

Results {#s3}
=======

[**Table 1**](#T1){ref-type="table"} shows the AUC~0--12h~ of caffeine, fexofenadine, midazolam metoprolol, α-OH metoprolol, omeprazole, and 5-OH omeprazol in the two phases of the study.

###### 

AUC~0--12h~ of the phenotypic probes and metabolites.

  Probes and metabolites   Training set (ng∙h^−1^∙mL^−1^)   Validation set (ng∙h^−1^∙mL^−1^)
  ------------------------ -------------------------------- ----------------------------------
  Caffeine                 1134.7 (627.6--1507.3)           1009.5 (584.0--1280.9)
  Fexofenadine             59.8 (48.4--84.6)                54.6 (47.6--60.0)
  Midazolam                1.1 (0.8--1.5)                   1.3 (1.0--1.7)
  Metoprolol               20.1 (10.5--47.4)                19.9 (10.8--50.8)
  α-OH metoprolol          31.5 (21.6--34.3)                30.3 (25.0--34.9)
  Omeprazole               20.7 (13.1--32.8)                18.3 (11.8--55.0)
  5-OH omeprazole          55.6 (46.7--69.3)                55.7 (47.4--86.9)

Development of LSS Models {#s3_1}
-------------------------

The plasma concentration data sets from the first study phase (training set) were used for development of the LSS models. The results of these analyses ([**Figure 1**](#f1){ref-type="fig"}) showed that single time-point LSS models provided *R* ^2^ values greater than 0.95 (*R* ^2^ \> 0.95) for the AUC~0--12h~ ratios of metoprolol: α-OH metoprolol and omeprazole/5-OH omeprazole. For the AUC~0--12h~ of caffeine, fexofenadine, and midazolam, a minimum of 2 time-points were required for LSS models with *R* ^2^ \> 0.95. Importantly, the sampling times for the best 1- or 2-point LSS models (i.e. those with the highest *R* ^2^ values) differed among the probes.

![Scatter plots of the effect of increasing the number of sampling time-points (abscissa) on the correlation coefficient (*R* ^2^, ordinate) between best-estimated AUC~0--12~s **(A--C)** or AUC~0--12h~ ratios **(D, E)** and the corresponding LSS-predicted metrics.](fphar-11-00022-g001){#f1}

We contrasted these LSS models to identify the sampling times that provided the highest combined *R* ^2^ values for all five probes. This exercise excluded time-points (0, 15, 30, 45, 360--720 min) with plasma concentrations below the limits of detection for one or more probes or metabolites in one or more subjects. For one-time models, only the 120 min sample provided *R* ^2^ \> 0.95 for both AUC~0--12h~ ratios of metoprolol: α-OH metoprolol and omeprazole/5-OH omeprazole, and the corresponding LSS models are presented in [**Table 2**](#T2){ref-type="table"}, with their regression equations, *R* ^2^, bias, and precision parameters. Four 2-point models provided average *R* ^2^ values greater than 0.95 for all five probes ([**Figure 2**](#f2){ref-type="fig"}). There was no statistically significant difference in *R* ^2^ values among the four models (ANOVA, p = 0.67), and all models comprised either or both 240 and 300 min samples. Considering that a shorter time of sample collection would be more convenient, we selected for further analysis the 2-point models which did not comprise 300 min samples i.e. the models with paired samples collected at 90 and 120 min or 90 and 240 min. The corresponding *R* ^2^, bias, and precision parameters ([**Table 2**](#T2){ref-type="table"}), indicate that these 2-point LSS models provide accurate estimates of the AUC~0--12h~s of caffeine, fexofenadine, and midazolam, and the ratios of AUC~0--12h~s of metoprolol: α-OH metoprolol and omeprazole:5-OH omeprazole.

###### 

*R* ^2^, bias, and precision of the LSS models.

  -------------------------------------------------------------------------------------------------------------------------------------
  Probe:metabolite\             LSS equations                                            *R* ^2^   MD% (mean ± SD)   MAD% (mean ± SD)
  sampling times (min)                                                                                               
  ----------------------------- -------------------------------------------------------- --------- ----------------- ------------------
  Caffeine                                                                                                           

  90, 240                       −59.306 + 3.030\*C~90~ + 5.699\*C~240~                   0.93      1.48 ± 13.67      11.81 ± 6.37

  120, 240                      86.649 + 1.372\*C~120~ + 7.018\*C~240~                   0.88      3.78 ± 16.04      12.99 ± 9.61

  90, 120, 240                  −64.496 + 2.969\*C~90~ + 0.458\*C~120~ + 5.193\*C~240~   0.93      1.54 ± 13;63      11.49 ± 6.89

  Fexofenadine                                                                                                       

  90, 240                       −5.830 + 2.614\*C~90~ + 4.818\*C~240~                    0.96      0.35 ± 8.39       7.08 ± 4.13

  120, 240                      −2.789 + 2.076\*C~120~ + 5.041\*C~240~                   0.90      1.59 ± 11.99      9.66 ± 6.85

  90, 120, 240                  −6.422 + 2.248\*C~90~ + 0.454\*C~120~ + 4.792\*C~240~    0.96      0.29 ± 8.13       6.82 ± 4.07

  Midazolam                                                                                                          

  90, 240                       −0.113 + 2.091\*C~90~ + 6.445\*C~240~                    0.97      0.38 ± 10.91      8.56 ± 6.41

  120, 240                      −0.081 + 4.710\*C~120~ + 0.720\*C~240~                   0.94      1.74 ± 13.31      11.51 ± 6.25

  90, 120, 240                  −0.114 + 2.069\*C~90~ + 0.061\*C~120~ + 6.365\*C~240~    0.97      0.37 ± 10.86      8.54 ± 6.36

  Metoprolol:α--OH metoprolol                                                                                        

  120                           −0.026 + 0.7416\*C~120~                                  0.98      −2.06 ± 12.33     9.57 ± 7.63

  90, 240                       0.024 + 0.063\*C~90~ + 0.783\*C~240~                     0.99      −1.64 ± 13.49     9.55 ± 9.34

  120, 240                      0.006 + 0.296\*C~120~ + 0.518\*C~240~                    1.00      −2.22 ± 9.27      6.39 ± 6.89

  90, 120, 240                  0.026 − 0.107\*C~90~ + 0.394\*C~120~ + 0.518\*C~240~     1.00      −0.54 ± 7.45      5.26 ± 5.12

  Omeprazole:5-OH omeprazole                                                                                         

  120                           0.041 + 0.8880\*C~120~                                   0.96      2.93 ± 16.46      16.57 ± 17.86

  90, 240                       0.100 + 0.272\*C~90~ + 0.7499\*C~240~                    0.92      6.77 ± 28.62      20.11 ± 20.90

  120, 240                      0.044 + 0.849\*C~120~ + 0.055\*C~240~                    0.96      3.13 ± 16.89      11.96 ± 11.96

  90, 120, 240                  0.021 − 0.655\*C~90~ + 1.974\*C~120~ − 0.401\*C~240~     0.98      1.52 ± 12.15      9.48 ± 7.36
  -------------------------------------------------------------------------------------------------------------------------------------

![Bar plots of the mean ± S.D. of the *R* ^2^ values for the correlation between the best-estimated and the LSS-predicted AUCs of caffeine, fexofenadine and midazolam, and the AUC ratios of parent drug to metabolite for omeprazole and metoprolol, using different combinations of two sampling times. The dotted vertical line indicates *R* ^2^ = 0.95.](fphar-11-00022-g002){#f2}

Increasing the number of sampling points to three (90, 120, and 240 min) led to relatively minor increases in *R* ^2^ and/or reductions in the bias or precision of the estimates ([**Table 2**](#T2){ref-type="table"}). Correlation plots of the best estimated *versus* the LSS-predicted AUC~0--12h~ metrics for each probe, and the respective Bland-Altman plots are shown in [**Supplementary Figures 1--5**](#SM1){ref-type="supplementary-material"}.

Validation of the LSS Models {#s3_2}
----------------------------

As a first validation procedure, the LSS equations derived from the training set, were applied to the data sets from the second study phase (validation set). The results shown in [**Table 3**](#T3){ref-type="table"} indicate that the single-point and 2-point LSS models derived from the development set provided accurate estimates of the respective metrics in the validation set, with *R* ^2^ values ranging from 0.89 to 0.98, except for midazolam, which showed lower *R* ^2^ values (0.73 and 0.81), but with bias and precision of estimates comparable to the other probes. Increasing the number of sampling points to three (90, 120, and 240 min) had no additional effect on the accuracy of the LSS for midazolam or the other probes.

###### 

Validation the LSS models.

  Probe:metabolite             *R* ^2^   MD% (mean ± SD)   MAD% (mean ± SD)
  ---------------------------- --------- ----------------- ------------------
  Caffeine                                                 
  90, 240                      0.95      3.60 ± 16.11      11.88 ± 11.08
  120, 240                     0.96      9.12 ± 11.53      11.39 ± 9.13
  Fexofenadine                                             
  90, 240                      0.94      2.04 ± 11.29      8.69 ± 7.16
  120, 240                     0.88      5.44 ± 12.19      10.29 ± 8.20
  Midazolam                                                
  90, 240                      0.81      5.63 ± 17.83      16.02 ± 8.83
  120, 240                     0.73      0.49 ± 22.62      14.67 ± 16.80
  Metoprolol:α-OH metoprolol                               
  120                          0.97      0.24 ± 12,98      11.42 ± 5.36
  90, 240                      0.97      5.12 ± 11.79      10.73 ± 6.60
  120, 240                     0.98      3.68 ± 10.42      8.40 ± 6.89
  Omeprazole:5-OH omeprazole                               
  120                          0.91      −4.48 ± 17.13     13.85 ± 10.51
  90, 240                      0.89      −0.14 ± 29.55     21.61 ± 19.36
  120, 240                     0.91      −4.20 ± 17.78     14.17 ± 11.00

As a second validation approach, the jack-knife resampling technique was applied. Results obtained for the development and validation data sets are shown separately in [**Table 4**](#T4){ref-type="table"}, and diagnostic plots for the validation set are presented in [**Figure 3**](#f3){ref-type="fig"}. *R* ^2^ values ranged from 0.73 (midazolam, 120 and 240 min, validation set) to 1.0 (metoprolol:α-OH metoprolol, two-point models, development set). Of notice, single-point models for metoprolol and omeprazole provided *R* ^2^ values \> 0.89 for both datasets.

###### 

*R* ^2^, bias (MD%), and precision (MAD%) for the jack-knife validation of LSS models.

  Probe:metabolite sampling times (min)   Training set         Validation set
  --------------------------------------- -------------------- ---------------------
  Caffeine                                                     
  90, 240                                 0.93 (1.48, 11.81)   0.95 (3.60, 11.88)
  120, 240                                0.88 (3.78, 12.99)   0.96 (9.12, 11.39)
  Fexofenadine                                                 
  90, 240                                 0.96 (0.35, 7.08)    0.94 (2.04, 8.69)
  120, 240                                0.90 (1.59, 9.66)    0.88 (5.44, 10.29)
  Midazolam                                                    
  90, 240                                 0.97 (0.37, 8.55)    0.81 (5.63, 16.02)
  120, 240                                0.94 (1.73, 11.51)   0.73 (0.49, 14.67)
  Omeprazole:5OH omeprazole                                    
  120                                     0.92 (6.76, 20.10)   0.89 (−0.14, 21.61)
  90, 240                                 0.96 (3.12, 11.94)   0.91 (−4.20, 14.17)
  120, 240                                0.98 (1.51, 9.46)    0.83 (−4.11, 17.14)
  Metoprolol:α-OH metoprolol                                   
  120                                     0.99 (−1.64, 8.96)   0.97 (5.12, 10.06)
  90, 240                                 1.00 (−2.22, 6.00)   0.98 (3.68, 7.88)
  120, 240                                1.00 (−0.55, 4.93)   0.97 (6.55, 9.28)

![Scatter plot of the relationship between the best-estimated AUC~0--12~s **(A--C)** or AUC~0--12h~ ratios **(D--E)** and the corresponding LSS-derived metrics using the jack-knife approach to the validation data set. The LSS models are distinguished by symbols: single point models (90 min), grey triangles; two-point models, open squares (90 and 240 min), black squares (120 and 240 min). The continuous line in each plot is the identity line.](fphar-11-00022-g003){#f3}

Discussion {#s4}
==========

In the present study, LSS strategies were applied to predict phenotypic metrics for a cocktail of probe drugs for CYP enzymes and the ABCB1 transporter. Plasma concentration data for the probe drugs and their metabolites in 2,640 samples collected from 16 closely monitored, healthy volunteers ([@B4]) were used for development and subsequent validation of LSS models. All the probe drugs, namely caffeine (CYP1A2 probe), midazolam (CYP3A), omeprazole (CYP2C19), metoprolol (CYP2D6), and fexofenadine (ABCB1) have been previously included, albeit in higher doses, in phenotypic cocktails, notably the Basel ([@B8]) and the Geneva cocktails ([@B2]). The phenotypic indices used to assess the activity of the CYPs and ABCB1 transporter have been previously validated. For example, the Basel cocktail used the AUC ratios of parent drug to metabolite for omeprazole and metoprolol ([@B8]), the Geneva cocktail used the AUC of fexofenadine ([@B2]), the Inje cocktail adopted the AUC of midazolam ([@B16]), and the caffeine AUC has been employed as a phenotypic metric for CYP1A2 activity in drug cocktail Interaction studies ([@B9]; [@B13]).

The LSS modeling disclosed single time-points which provided highly accurate (*R* ^2^ \> 0.95) estimates of the AUC~0--12h~ ratios for metoprolol: α-OH metoprolol and omeprazole:5-OH omeprazole. This supports the adoption of single point metabolic ratios for metoprolol (90, 120, or 240 min) and omeprazole (120 min) as reliable parameters of CYP2D6 and CYP2C19 activity, respectively. For the other drugs examined, namely caffeine, fexofenadine, and midazolam, 2-timed samples were required to obtain predictions of the respective phenotypic metrics with *R* ^2^ values exceeding 0.95. Although the most informative time points differed among these drug probes, LSS models based on paired samples collected at 90 and 120 min or 90 and 240 min provided *R* ^2^ values in the range of 0.88 to 1.0 for their respective phenotypic metrics in the development cohort ([**Table 3**](#T3){ref-type="table"}). Increasing the number of sampling points to three (90, 120, and 240 min) led to relatively minor increases in *R* ^2^ and/or reductions in the bias or precision of the estimates. The statistical principle of parsimony advises in favor of models with fewer parameters; accordingly, the two-point LSS models (90 and 120 min; 120 and 240 min) for all drug probes plus the single-point models (120 min) for metoprolol and omeprazole were chosen for independent validation. The two validation tests confirmed the robustness of the LSS models over wide ranges (\> 5 fold) of phenotypic metrics values ([**Figure 3**](#f3){ref-type="fig"}). We suggest that the validated LSS models are appropriate for predicting phenotypic indices for CYP1A2, CYP2C19, CYP2D6 CYP3A, and the ABCB1 transporter, using subtherapeutic doses of caffeine, omeprazole, metoprolol, midazolam, and fexofenadine, respectively.

Several phenotypic cocktails propose single-point plasma sampling for assessment of phenotypic indices for CYPs and ABCB1 (reviewed by [@B10]; [@B6]; [@B11]). The present results supports this approach when metoprolol and omeprazole are used, respectively, as phenotypic probes for CYP2D6 and CYP2C19 activity. However, including one additional sampling point increases the predictive power of phenotypic indices for caffeine, midazolam, and fexofenadine.

We acknowledge limitations of this study: first, CYP2D6 poor metabolizers were not included in the LSS modeling; thus, the single-point and two-point models for metoprolol may not be extended to individuals with this phenotype. Two other potential limitations are the relatively small size of our study cohort (n = 16) and the fact that it comprised only healthy subjects. However, these same limitations apply to the development of several other phenotyping cocktails, such as the Basel (n = 16; [@B8]), Inje (n = 12; [@B16]), Cooperstown (n = 12; [@B20]), Karolinska (n = 24; [@B3]), Quebec (n = 10; [@B19]), and the Ceiba cocktail (n = 13; [@B7]). Of notice, among these phenotypic cocktails, only the CEIBA was developed in another Latin American population, namely Equatorians. Finally, our modeling is based on data from low, subtherapeutic doses of the probe drugs, and the phenotypic metrics analyzed may not have a linear relationship to the enzyme and transporter activities when higher probe doses are used.

Data Availability Statement {#s5}
===========================

The authors declare that all data supporting the findings of this study are available within the article and its [**Supplementary Materials**](#SM1){ref-type="supplementary-material"}, or from the corresponding author on request.

Ethics Statement {#s6}
================

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all subjects included in the study.

Author Contributions {#s7}
====================

EC: responsible for research ethics application, data analyses, and reviewing the manuscript. DC: responsible for research ethics application, data collection, and analyses, and reviewing the manuscript. JX: responsible for development of limited sampling modeling and reviewing the manuscript. VL: responsible for data analyses and interpretation, and reviewing the manuscript. CS: responsible for development of limited sampling modeling and reviewing the manuscript. GS-K: responsible for study design, data analyses and interpretation, and writing the original manuscript.

Funding {#s8}
=======

GS-K was a Visiting Professor at Faculdade de Ciências Farmacêuticas de Ribeirão Preto, sponsored by Universidade de São Paulo (USP). The authors acknowledge grant support from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Fundação de Apoio à Assistência, Ensino e Pesquisa HCFMRP-USP (FAEPA), Departamento de Ciência e Tecnologia, Ministério da Saúde (DECIT/MS), and Financiadora de Estudos e Projetos (FINEP).

Conflict of Interest {#s9}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material {#s10}
======================

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00022/full#supplementary-material>

###### 

Click here for additional data file.

[^1]: Edited by: Miia Turpeinen, Oulu University Hospital, Finland

[^2]: Reviewed by: Pedro Dorado, University of Extremadura, Spain; Andrew McLachlan, University of Sydney, Australia

[^3]: This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology
